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Received 16 October 2014; revised 24 October 2014; accepted 19 November 2014AbstractHearing loss (HL) is one of the most widespread sensory disorders, affecting approximately 1 in 500 newborns. Heritable diseases of the
inner ear are the leading causes of prelingual HL. Treating of hereditary HL and understanding its underlying mechanisms remain difficult
challenges to otolaryngologists. As stem cells are capable of self-renewal and differentiation, they are ideally suited both for disease modeling
and regenerative medicine. Recently, description of induced pluripotent stem cells (iPSCs) has allowed the field of disease modeling and
personalized therapy to become far more accessible and physiologically relevant, as iPSCs can be generated from patients of any genetic
background. This review briefly describes the advantages of iPSCs technology and discusses potential applications of this powerful biological
tool in studying and treating hereditary HL.
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Hearing loss (HL) is one of the most common birth defects
and prevalent sensorineural disorders, affecting approximately
1 in 500 newborns with bilateral congenital sensorineural
hearing loss 40 dB HL (Hilgert et al., 2009a). More than
two-thirds of prelingual HL cases are attributed to hereditary
factors, most of which are caused by mutations of a single
gene that functions in the inner ear (Hilgert et al., 2009a;
Morton and Nance, 2006). HL can be present in a non-
syndromic form (70%), as a single disorder, or syndromic
form (30%) associated with distinctive clinical features
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Ltd. This is an open access article under the CC BY-NC-ND license (http://creativCongenital Hearing Loss, 2002). More than 150 chromosomal
loci and at least 80 genes have been identified to result in non-
syndromic as well as syndromic forms of HL, and approxi-
mately 1000 causing mutations have been described (Hilgert
et al., 2009a, 2009b). Due to unclear mechanisms underlying
hereditary HL and the intricate microstructure of the inner ear,
treatment of hereditary HL is still a huge challenge to oto-
laryngologists. Stem cells capable of self-renewal and differ-
entiation are ideally suited both for generating disease models
and for obtaining the large quantities of cells required for
genetic correction and transplantation therapies. Three major
types of stem cells have been adopted: embryonic stem cells
(ESCs), adult stem cells (ASCs), and induced pluripotent stem
cells (iPSCs). Especially in recent years, significant advances
have been made in the research of inherited disease by iPSC
technology, opening an avenue to generate patient-specific
pluripotent stem cells. With the presence of retroviral inte-
gration, human iPSCs are useful in understanding disease
mechanisms, drug screening, and regenerative mediciney Head and Neck Surgery. Production and hosting by Elsevier (Singapore) Pte
ecommons.org/licenses/by-nc-nd/4.0/).
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application for neurodegenerative diseases, blood disorders
and retinal degenerative diseases, but little is known for he-
reditary HL (Wiley et al., 2015; Ross and Akimov, 2014;
Wang et al., 2012). In this review, we will briefly describe
the advent of iPSCs technology and discuss potential appli-
cations of this powerful biological tool in studying and treating
hereditary HL.
2. Comparison among three types of stem cells
All three types of stem cells contain two remarkable
cellular characteristics that make them ideal candidates for
regenerative medicine applications: the properties of “self-
renewal” and “pluripotency”. Self-renewal refers to the ability
of these cells to make identical copies of themselves indefi-
nitely, without developing chromosomal abnormalities or un-
dergoing growth arrest. Pluripotency refers to the ability of
these cells to differentiate into any cell of the human body,
following the natural path of human embryonic development,
when given the appropriate signals.
ESCs are harvested from the inner cell mass of the blas-
tocyst of 5-day-old pre-implantation embryos. As ESCs can
differentiate into the three germ layers, they are a popular tool
used in regenerative medicine. ASCs are undifferentiated cells,
found throughout the body after development that multiply by
cell division to replenish dying cells and regenerate damaged
tissues. These cells are suggested to be present in small
numbers in most major organs, such as bone marrow, skin,
brain and inner ear (Davanger and Evensen, 1971; Gage, 2000;
Li et al., 2003). ESCs have played a substantial role in disease
modeling and treatment studies in the past decades, however,
harvesting ESCs from the inner cell mass of the blastocyst
during development restricts their clinical practicality due to
limited availability and ethical concerns. In addition, ESCs are
by definition non-autologous, not derived from the patient for
which they are destined, and for cell transplantation an addi-
tional obstacle of immune incompatibility exists (Wiley et al.,
2015). Although the use of ASCs has no ethical issues and less
concerns for immune rejection, limited potency and capacity
for self-renewal hinders their further research.
Yamanaka and his colleagues revolutionized the stem cell
field in 2006 when they demonstrated that murine fibroblasts
could be reprogrammed into ESC-like pluripotent stem cells
by transfecting four transcription factors, Klf4, Oct3/4, Sox2,
and c-Myc (KOSM), termed induced pluripotent stem cells
(iPSCs) (Takahashi and Yamanaka, 2006). One year later,
Yamanaka's group successfully derived iPSCs also from
human fibroblasts, thus making his work relevant to human
disease and an incredibly promising potential resource for
cellular transplantation studies (Takahashi et al., 2007). True
pluripotency of iPSCs has been demonstrated by successful
production of viable mice from iPSCs through tetraploid
complementation (Zhao et al., 2009). However, in conven-
tional transduction, retroviral vectors are randomly integrated
into the host's genome, thus significantly increasing the risk of
insertional mutagenesis and oncogenesis (Okita et al., 2013).In order to generate clinical-grade iPSCs, safer methods have
become the main goal of development in reprogramming
technology. The most promising are DNA-free and viral-free
protocols. They include introduction of reprogramming-
inducing molecules into cells such as: recombinant proteins,
messenger RNA (mRNA), and mature microRNA (miRNA)
(Kim et al., 2009; Warren et al., 2010; Miyoshi et al., 2011).
The efficiency of non-integrating reprogramming methods is
significantly enhanced by the use of low oxygen level condi-
tions and small molecules such as histone deacetylase in-
hibitors and/or DNA methyltransferase inhibitors
(Szablowska-Gadomska et al., 2011; Huangfu et al., 2008;
Mikkelsen et al., 2008). The traditional methods of obtaining
somatic cells requires harvesting skin specimens, which in-
creases patient's discomfort. Some researchers have found that
other human somatic cells derived from blood or urine sam-
ples also can be reprogrammed into iPSCs, which greatly
facilitate their clinical applications (Zhou et al., 2012; Staerk
et al., 2010).
The discovery of iPSC ushered in a new age in the field of
disease modeling and regenerative medicine. Unlike ESCs, the
human iPSCs are not constrained by ethical disputes, and,
although not yet fully tested, they should be safer immuno-
logically (Wiley et al., 2015). A key advantage of the iPSC
technology is that these cells can be generated in large
numbers using cells taken from the patients for which they are
intended. Hence, iPSCs are patient-specific. Additionally, like
ESCs, iPSCs are pluripotent and can be differentiated into any
cell type of the three embryonic germ layers (Takahashi et al.,
2007).
3. Contribution of IPSCs to hearing research3.1. Hereditary hearing loss modelingMost hereditary HL cases are caused by monogenic mu-
tations (Angeli et al., 2012). They are usually manifested by
functional defect of the organ of Corti e a structure of
receiving, encoding and transmitting acoustic signals to higher
auditory processing stations. Since the discovery of the first
nonsyndromic deafness gene in 1993, more than 150 loci of
deafness genes have been mapped and more than 80 genes
have been implicated in nonsyndromic HL. These genes fall
into four broad functional categories: hair bundle morpho-
genesis, ion homeostasis, extracellular matrix composition and
transcription factors (Hilgert et al., 2009a; Yan and Liu, 2008).
Spontaneous and induced mouse models of hereditary HL are
routinely used for understanding of genesbiological relevance
to auditory function. However, producing knockout, knock-in
and conditional mutant gene-targeted mice is a high-cost and
time-consuming process, especially knockout of certain genes
such as BMP4 will cause the mouse to die before the inner ear
is formed (Hogan et al., 1994). In addition, such models rarely
mirror human disease pathological mechanisms, and the
human response is often difficult to be predicted from these
models (Blanton et al., 2002). It is assumed that patient-
derived iPSCs can replace millions of animals currently
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generate model organism. The first analysis of a disease-
specific mutation was that of JAK2-V617F in myeloprolifer-
ative disease in 2009 (Ye et al., 2009). Since then, several
diseases have been modeled using iPSC technology. For
example, patient-specific Alzheimer's disease iPSCs were
produced that displayed the differences of pathological
markers compared to controls (Israel et al., 2012). Thus,
through the generation and analyses of iPSCs from normal
subjects and hereditary disease patients, we will improved
cellular and molecular understanding of human hereditary HL
(Fig. 1).
It is believed that iPSCs are a useful tool for the interro-
gation of disease pathophysiology in relatively inaccessible
tissues such as the inner ear that cannot be routinely subjected
to molecular analysis in living patients. Critical point for the
ability to model hereditary HL is the capacity to generate inner
cells from iPSCs. A study presented a stepwise guidance
protocol starting with iPSCs, which were directed toward
becoming ectoderm capable of responding to otic-inducing
growth factors (Oshima et al., 2010). The resulting otic pro-
genitor cells were plated onto a layer of mitotically-inactivated
chicken utricle stromal cells, which promoted the organization
of the cells into epithelial clusters displaying hair cell-like
cells with stereociliary bundles that were labeled with phal-
loidin and antibody to espin (Oshima et al., 2010). Bundle-
bearing cells in these clusters responded to mechanical stim-
ulation with currents that were reminiscent of immature hair
cell transduction currents (Oshima et al., 2010). Another study
showed that neurite outgrowth from iPSC-derived neural
progenitors toward cochlear hair cells ex vivo, and followedFig. 1. Schema of how induced pluripotent stem cell (iPSC) can be applied in a c
directly into inner ear cells and transplanted back into the patient to model hereditheir expressed markers for glutamatergic neurons after
transplantation into mouse cochleae in vivo (Nishimura et al.,
2009). Neurons derived from iPSCs projected neurites toward
cochlear hair cells (Nishimura et al., 2009). These findings
indicate that iPSCs can be differentiated into hair cell-like
cells and spiral ganglion neurons, therefore, it is feasible to
model hereditary HL by using patient-derived iPSCs.3.2. Genetic correction and cell replacement treatmentDespite that hearing aids and cochlear implants are rela-
tively satisfactory solution for hereditary HL, future treatment
will have to rely on basic rather than symptomatic approaches.
A new treatment strategy is to create immunologically-
matched and genetically-corrected hair cells or spiral gan-
glion neurons that can be transplanted into the cochlea to
restore hearing. An ideal inner ear cells source of no immune
rejection is patient-specific iPSCs, and recent advances in
genome editing approaches, including the use of zinc finger
nucleases (ZFNs), transcription activator-like effector nucle-
ases (TALENs) and clustered, regularly interspaced, short
palindromic repeat (CRISPR)/CRISPR-associated nuclease 9
(Cas9), are especially exciting for the potential boost to ge-
netic correction of cellular level (Christian et al., 2010;
Hockemeyer et al., 2011; Miller et al., 2007). The simplicity
of design makes CRISPR/Cas9 more promising than the other
two genome editing techniques. Components of the prokary-
otic CRISPR/Cas9 adaptive immune system have enabled the
development of RNA-guided nuclease technology for targeted
genome editing (Cong et al., 2013; Maeder et al., 2013). The
S. pyogenes Cas9 can be directed by a ~100 nt single guidelinical setting. These iPSCs may contain a mutation that can be differentiated
tary diseases of hearing loss or to correct them using gene therapy.
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complementary to the first 20 nts of the sgRNA and flanked by
a protospacer adjacent motif (PAM) sequence of the form
NGG (Jinek et al., 2012). Similarly to ZFN- and TALEN-
mediated gene correction, cells repair the majority of
CRISPR/Cas9-induced doublestrand breaks (DSBs) by both
homologous and non-homologous mechanisms. Applications
based on the two DSB repair pathways lead to introduction of
different types of mutations at target-specific sites of the
genome including gene knock-out, knock-in and point muta-
tions. In the absence of a homologous repair template, the cell
naturally employs nonhomologous end joining (NHEJ) lead-
ing to the insertion or deletion (InDel) of sequence sur-
rounding the DSB (Sun et al., 2012). Repair via NHEJ
represents a feasible strategy for intronic mutations in areas of
poorly conserved sequence. However, to correct loci at which
large deletions or insertions occur or where NHEJ-mediated
InDels would not be tolerated, the sgRNAs and Cas9 must
be co-delivered with an engineered repair template containing
unmutated wild-type sequence. DSB repair occurs via ho-
mologous recombination using the exogenous repair sequence
as template. Homology-directed repair (HDR) in diseased
patient cells harboring mutations would presumably restore
wild-type gene and protein expression and function. The un-
avoidable off-target effects have largely restrict the application
of CRISPR/Cas9 indirectly genome editing of target cells
in vivo, but iPSC technology provides a large number of
candidates which could be used to screen non-off-target cells.
Thus, following CRISPR-based correction, iPSCs-derived
inner ear cells to be used for human transplantation would
no longer harbor disease-causing mutations.
Patient-specific iPSCs technology coupled with CRISPR/
Cas9 have the potential to elevate stem cell replacement
therapy to being a long-term disease remedy. CRISPR/Cas9
has been shown to precisely correct the dystrophin gene in
Duchenne muscular dystrophy (DMD) patient-specific iPSCs
(Li et al., 2015). To restore the dystrophin protein, Akitsu
Hotta's group performed three correction methods (exon
skipping, frameshifting, and exon knockin) by CRISPR/Cas9
in DMD patient-specific iPSCs, and found that exon knockin
was the most effective approach (Li et al., 2015). Finally, they
differentiated the corrected iPSCs toward skeletal muscle cells
and successfully detected the expression of full-length dys-
trophin protein (Li et al., 2015). These results provide an
important framework for developing iPSC-based gene therapy
for hereditary HL using programmable nucleases.
4. Future directions
Many exciting developments in the field of iPSC technol-
ogy present an excellent opportunity to treat hereditary HL
and ultimately improve patients' lives. iPSCs can be employed
to investigate and determine disease mechanisms from indi-
vidual patients. Knowledge gained from these experiments can
be used to develop gene-based therapies. Transplantation of
gene-corrected patient-specific iPSC-derived inner ear cells
will treat individuals with hereditary HL. These approacheswill be expedited through production of clinical-grade re-
agents in the near future, so that therapeutics can reach human
patients more quickly.
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